Core Viewpoint - The successful listing of Beixin Life Technology Co., Ltd. on the STAR Market marks the first successful IPO under the "fifth set of standards" for innovative medical device companies, highlighting the potential for growth in the cardiovascular precision diagnosis and treatment sector [1][4]. Company Overview - Beixin Life focuses on the research, development, production, and sales of innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, with 17 approved and in-development products as of September 30, 2025 [4]. - The company has incurred significant losses due to high R&D and market promotion costs, with a cumulative undistributed profit of -690 million yuan as of June 30, 2025, but is now moving towards profitability as commercialization progresses [4][7]. Financial Performance - Revenue for Beixin Life is projected to grow significantly, with estimates of 520 million to 560 million yuan for 2025, representing a year-on-year increase of 64.24% to 76.88%, and a net profit of 78 million to 88 million yuan, marking a turnaround from previous losses [7]. - The company raised a total of 999 million yuan in its IPO, with a net amount of 899 million yuan allocated primarily for the construction of an interventional medical device industrial base and R&D [7]. R&D and Innovation - Beixin Life has consistently increased its R&D investment, totaling 389 million yuan over the past three years, with a workforce of 100 R&D personnel, over 40% of whom hold advanced degrees [6]. - The company has launched 11 products to market and has 6 products in development, with its core IVUS and FFR systems having received regulatory approval and achieving significant market share [6][8]. Market Position and Competition - The IVUS system is the first domestically approved 60MHz high-definition product and has captured a leading market position, while the FFR system holds a 30.6% market share shortly after its launch [6][10]. - Despite the competitive landscape, with established international players and other domestic manufacturers, the market for IVUS and FFR is expected to grow significantly, with projections indicating a compound annual growth rate of approximately 19.4% to 21.1% through 2030 [10]. Challenges and Risks - Beixin Life faces challenges from increasing competition and potential risks related to product commercialization and R&D failures, as well as pressures from centralized procurement policies that could impact pricing and market share [9][10]. - The company’s stock is currently trading at a higher price-to-sales ratio compared to industry peers, which may pose risks for investors if market conditions change [11].

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. (Beixin Life) officially listed on the Sci-Tech Innovation Board on February 5, 2026, under the stock code "688712.SH," marking it as the first medical device company to successfully list under the new fifth set of standards since its restart and the first medical device company to list in 2024 [3]. Group 1: Company Overview - Beixin Life is the first domestic medical device company with a product portfolio that includes intravascular functional flow reserve (FFR) and intravascular ultrasound (IVUS) [3]. - The company has received investments from several well-known institutions, including Qiming Venture Partners, which led its Series C financing in 2020 and continued to support its development in Series D financing [4]. Group 2: Investment Insights - Qiming Venture Partners holds over 6% of Beixin Life's shares prior to the IPO, indicating its role as a major institutional investor [4]. - The firm has a strong interest in the cardiovascular and other medical device sectors, having a history of successful cases in these fields [4]. Group 3: Strategic Approach - Beixin Life's strategy focuses on building a robust product portfolio and company capabilities rather than merely pursuing rapid registration, emphasizing the creation of differentiated and competitive products [5]. - The company has maintained this strategy for over a decade, which has instilled confidence among shareholders [5]. Group 4: Future Expectations - Post-IPO, Beixin Life is expected to continue strengthening its product line in the coronary field and expand into high-potential new areas such as electrophysiology [5]. - There is significant untapped international market potential for Beixin Life's products, with plans for deeper internationalization following the IPO [5]. Group 5: Market Context - In 2025, Qiming Venture Partners invested in over 30 projects in the medical innovation sector, contributing more than 3 billion yuan, despite a cautious investment environment in the medical sector [5]. - The firm maintains strong confidence in the fundamentals of Chinese medical innovation, believing that China's clinical experience, engineering teams, and entrepreneurial spirit can foster globally competitive medical device products [6].

红杉中国董事总经理曹弋博（左）与北芯生命创始人、董事长兼CEO宋亮博士在上市仪式 现场。 本文为IPO早知道原创 作者｜ Stone Jin 微信公众号｜ipozaozhidao 据IPO早知道消息，深圳北芯生命科技股份有限公司（以下简称"北芯生命"）于2026年2月5日正式 以"688712.SH"为股票代码在上海证券交易所科创板挂牌上市。 值得一提的是， 北芯生命是重启科创板第五套标准后，该标准下第三家、医疗器械行业首家成功上 市企业，也是2024年以来首家在科创板成功上市的医疗器械企业。 作为国内首家拥有血管内功能学血流储备分数（FFR）及影像学血管内超声（IVUS）产品组合的国 产医疗器械公司，北芯生命自成立以来已获得红杉中国等多家知名机构的投资。 其中， 红杉中国于2018年领投了北芯生命的B轮融资且在后续各轮融资中持续支持。IPO前，红杉 中国持有北芯生 命超10%的股份，为公司最大机构投资方，红杉中国董事总经理曹弋博担任北芯生 命董事，也是在北芯生命服务时间最长的投资人董事 曹弋博表示："北芯生命是红杉中国深耕心血管精准诊疗赛道的重要战略布局。我们认为，真正的国 产替代不应止步于复制，而在于超越 ...

Core Viewpoint - Shenzhen Beixin Life Technology Co., Ltd. has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking it as the first medical device company to do so in 2024 and the first under the new fifth set of standards for the board [2][12]. Company Overview - Established in 2015, Beixin Life focuses on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases, aiming to transform clinical practices [6][10]. - The company has launched 11 products and has 6 more in development, covering various categories including IVUS systems and FFR systems [6]. Product Highlights - The core product, the IVUS system, is the first domestically developed 60MHz high-definition IVUS product approved by the National Medical Products Administration, featuring high definition, speed, and intelligence [7]. - The FFR system is recognized as the gold standard for PCI treatment guidance and has received high-level recommendations in multiple domestic and international guidelines [7]. - Beixin Life's PFA system is the first in China to be included in breakthrough clinical research at the European Society of Cardiology [8]. Market Impact - The successful launch of Beixin Life's products has filled a significant gap in the domestic market, previously reliant on imported products for precise cardiovascular diagnosis [7][10]. - The company has established a presence in over 30 provinces in China and has clinical applications in more than 1,000 hospitals globally, including in Belgium, Germany, and Italy [8]. Innovation and R&D - Beixin Life emphasizes long-term independent research and technological innovation, having developed four core technology platforms for medical devices [10]. - The company holds 185 domestic and international patents, including 86 invention patents and 14 PCT international patent applications [10]. Future Prospects - The listing is seen as a new starting point for Beixin Life, enabling it to accelerate development in innovation, global market expansion, and capital collaboration [12]. - The cardiovascular intervention field is expected to see significant growth, driven by increasing clinical needs and technological advancements [11]. Investment and Support - Major institutional investors include Sequoia China and Qiming Venture Partners, who have expressed confidence in Beixin Life's innovative capabilities and market potential [14][15]. - The company has received continuous support from its investors, focusing on building a strong product portfolio and enhancing its competitive edge in the market [15][17].

Core Viewpoint - North Chip Life Technology Co., Ltd. successfully listed on the Sci-Tech Innovation Board, marking a significant milestone for the company and the medical device industry in China, with strong investor interest reflected in a subscription multiple of 4595.20 times during the IPO process [1][7]. Company Overview - North Chip Life is the first medical device company to successfully list under the fifth set of standards of the Sci-Tech Innovation Board, emphasizing support for innovative high-end manufacturing enterprises with original technology [1][2]. - The company is recognized for its core products, the intravascular ultrasound (IVUS) diagnostic system and the fractional flow reserve (FFR) measurement system, which are the first domestically approved products in China [3][4]. Market Potential - The market for PCI (Percutaneous Coronary Intervention) procedures in China has surpassed one million annually, yet the penetration rate of IVUS and FFR products remains low, indicating significant growth potential [4][9]. - The company’s FFR system captured 30.6% of the domestic market share in its first year, while the IVUS system has reached approximately 1,000 hospitals since its launch in 2022 [4][5]. Financial Projections - North Chip Life projects revenue for 2025 to be between 520 million to 560 million yuan, representing a year-on-year increase of 64.24% to 76.88%, with net profit expected to reach 78 million to 88 million yuan, indicating a nearly threefold growth [1][10]. R&D and Innovation - The company has invested 389 million yuan in R&D from 2022 to 2024, with R&D expenses projected to account for 35.65% of revenue in 2024 [5][6]. - North Chip Life holds 185 domestic and international patents, with a strong focus on developing a comprehensive product line that includes 17 products across five categories [6]. Recognition and Achievements - The company has received multiple accolades, including recognition as a national "little giant" enterprise and awards for its innovative medical devices, further establishing its credibility in the market [6].

研究团队首先构建了一种可贴附、可定制的柔性磁定位贴片，这种贴片基于柔性印刷电路板构建， 整体结构轻薄、柔软，可根据具体需求，设计成不同形状与尺寸，能贴附于皮肤表面，或集成于探头、 内镜等医疗器械表面，能够"即贴即用"，如同装上"柔性GPS"，为操作医疗器械提供精准指引。 中国科学院深圳先进技术研究院(简称"深圳先进院")集成所研究员徐天添团队联合浙江大学研究员 陆豪健团队在《自然—传感器》上发表最新研究。合作团队开发出了一种可贴附、可定制的柔性磁定位 贴片系统，并构建了"双阶段磁定位"策略，有望为微创手术中医疗器械的操作提供高精度、实时跟踪的 新策略。 在血管介入手术、消化道内镜手术、辅助手术机器人等微创手术中，对医疗器械进行实时、精准的 三维"导航"，是保障手术安全与操作效率的重要基础。CT、MRI和数字减影血管造影(DSA)等影像技术 可贴附、可定制的柔性磁定位贴片。研究团队供图 集成了柔性磁定位贴片的 ERCP 镜用于磁性导丝定位实验。研究团队供图 虽能提供一定的"导航"信息，但设备体量大、依赖特定的手术环境且大多只能提供二维信息，还存在辐 射暴露风险。 近年来，磁场定位技术被逐渐引入医疗领域，展现出了 ...

Core Viewpoint - North Chip Life has successfully listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board, marking a significant milestone as the first medical device company to do so under the new fifth set of standards, with an opening price that surged 187% from the issue price [2][4]. Group 1: Company Overview - North Chip Life is recognized as a "hexagonal warrior" in the medical device industry, demonstrating balanced development across product innovation, global market entry, commercialization, and profitability [4][12]. - The company focuses on innovative and high-quality cardiovascular precision intervention solutions, aiming to fill the technological gaps in China's medical device industry [5][6]. Group 2: Investment and Support - Sequoia China has been a key investor since 2018, providing continuous support in strategic choices, operational advice, and international promotion [5][6][9]. - The investment team at Sequoia China identified the potential in North Chip Life's technology, leading to significant funding and strategic guidance throughout the company's growth [9][10]. Group 3: Product Innovation - North Chip Life has developed the first domestically approved 60MHz high-speed IVUS product and a domestic FFR measurement system, showcasing the capability of Chinese companies to redefine market standards through technological advancements [6][12]. - The company emphasizes differentiated innovation in its product development, addressing clinical pain points rather than merely replicating existing products [12][13]. Group 4: Market Expansion - North Chip Life has established strategic partnerships to enhance its overseas market presence, with international sales contributing over 15% of its revenue as of September 30, 2025 [10]. - The company is actively expanding its product offerings in the cardiovascular diagnosis and treatment sectors, focusing on high-performance and high-barrier medical devices [12][13].

Group 1 - The core viewpoint of the article is that Beixin Life (688712) has been listed on the Shanghai Stock Exchange, focusing on innovative medical devices for precise diagnosis and treatment of cardiovascular diseases [1] - Beixin Life is recognized as a national high-tech enterprise dedicated to developing transformative solutions for cardiovascular disease diagnosis and treatment [1] - As of September 30, 2025, the company has no single shareholder holding more than 30% of the shares, indicating a relatively dispersed ownership structure [1] Group 2 - The largest shareholder, Song Liang, directly holds 16.1530% of the company's shares and controls an additional 13.4140% through partnerships, giving him a total voting power of 29.5670% [1] - After the recent issuance, Song Liang's direct shareholding is 13.9450%, with an additional 11.5804% controlled through partnerships, resulting in a total voting power of 25.5254% [1] - The total amount raised from the issuance is 998.64 million yuan, with a net amount of 898.89 million yuan allocated for the construction of an interventional medical device industrialization base, R&D projects, and to supplement working capital [2]

Core Insights - In 2025, Shaanxi aims to enhance law enforcement collaboration across provincial and municipal levels, targeting 2,678 cases related to "two products and one device" (drugs, cosmetics, and medical devices) and transferring 56 cases to judicial authorities [1] Group 1: Regulatory Focus - Shaanxi's regulatory efforts have concentrated on high-risk enterprises, high-risk products, and critical production processes, ensuring compliance with drug quality management standards [1] - The province has implemented a "rectification follow-up" mechanism to track the compliance of enterprises with corrective actions [1] Group 2: Online Sales Regulation - To address challenges posed by online drug sales, Shaanxi has strengthened integrated supervision of online and offline sales, emphasizing corporate responsibility [1] - The province is focusing on cracking down on illegal online drug sales, including unqualified sales and prescription drugs sold without prescriptions [1] Group 3: Regulatory Efficiency - Shaanxi is promoting service-oriented law enforcement in drug regulation, allowing for leniency in minor violations through a "first violation not penalized" list [1] - The province is also piloting reforms to optimize the review and approval process for supplementary drug applications [1] Group 4: Future Initiatives - Shaanxi plans to enhance high-level regulation throughout the drug lifecycle, continuing initiatives such as the "clean source" action in drug operations and a three-year improvement plan for cosmetic production quality management systems [2]

Group 1: Regulatory Support for Biomanufacturing - The National Medical Products Administration (NMPA) will strongly support the innovation and development of the biomanufacturing industry during the 14th Five-Year Plan period, transitioning from "follow-up innovation" to "systematic innovation" [1] - The NMPA aims to accelerate the approval process for new drugs, focusing on new drug targets, AI-driven drug development, and cutting-edge technologies like cell and gene therapy [1] - A digital platform will be established to provide a one-stop consultation service for enterprises, enhancing compliance and technical guidance [1] Group 2: Mental Health Insurance Regulation - The National Healthcare Security Administration (NHSA) is conducting collective talks with heads of mental health insurance designated medical institutions to strengthen management and combat illegal use of insurance funds [2] - Institutions are required to conduct self-inspections focusing on fraudulent practices, with reports due by March 15 [2][3] - The NHSA will implement special inspections and impose severe penalties on institutions that fail to comply with regulations [3] Group 3: Clinical Trials and Approvals - Shouyao Holdings announced that its MAT2A inhibitor SY-9453 has received approval for clinical trials to treat advanced or metastatic solid tumors with MTAP gene deletion [4] - Sainuo Medical has received a medical device registration certificate for its drug-eluting stent system aimed at treating ischemic heart disease [5] - Zhifei Biological has obtained approval for clinical trials of its lyophilized varicella inactivated vaccine [7] Group 4: Strategic Collaborations and Innovations - Zhejiang Provincial Food and Drug Inspection Institute signed a strategic cooperation agreement with Hikvision to promote innovation in scientific instruments [8] - The Brain-Machine Interface and Human-Machine Integration Laboratory has launched China's first "Traditional Chinese Medicine Brain-Machine Interface" equipment, integrating acupuncture with smart wearable technology [9] Group 5: Market Transactions and Financial Activities - Shanghai Pharmaceuticals plans to publicly transfer a 30% stake in China Shanghai Pharmaceuticals to raise at least 1.023 billion yuan [12] - Xinbang Pharmaceutical provided a 40 million yuan guarantee for its subsidiary Guizhou Tongde Pharmaceutical [13] - Pianzaihuang's controlling shareholder received a loan commitment for up to 450 million yuan to support share buybacks [14][15]